An another setback for biosimilars: Celltrion halts trial of biosimilar Rituxan/Mabthera

April 19, 2013 4:23 PM

According to a report by Bloomberg, the South Korean biosimilar company, Celltrion has stopped the clinical trial of a biosimilar version of Rituxan/Mabthera. 

The drug, rituximab, which is known as Rituxan in the US and Mabthera in the rest of the world is a monoclonal antibody which is used to treat several types of lymphoma and also rheumatoid arthritis.

Celltrion, the South Korean biosimilar company, is developing several biosimilars and also registered their first biosimilar, infliximab in their home country. The product, Remsima is still under review in several countries around the globe, including the European Union.

As Bloomberg reported, Celltrion aimed to advance its biosimilar candidate CT-P10 into Phase III development this year, yet the European Medicines Agency’s clinical trials registry lists the planned study for patients with non-Hodgkin lymphoma as terminated.

According to Bloomberg report, it is not clear what prompted the change, and if the South Korea-based company will resume the trial later.

Companies such as Boehringer and Novartis’ Sandoz unit are racing to bring a biosimilar version of the drug but last year, we received a similar information from Teva, the Israeli-company and it seems we will have to wait more to see the first successfully developed biosimilar of rituximab.


Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!